Pharvaris heads into the week after Q1 earnings with a complex mix: a clean beat, a fresh equity raise, meaningful insider selling, and short sellers retreating sharply.
The clearest catalyst was Q1 results delivered on May 12. Pharvaris reported EPS of -$0.69, beating the -$0.77 consensus by $0.08. The same day, the company closed a $132.3 million underwritten share offering — including full exercise of the overallotment option. Stock closed at $31.25, up 4.3% on the day and 4.1% for the week, extending a 17% one-month run.
The insider picture is the most attention-grabbing angle right now. Multiple founders and senior executives sold into the May earnings window. The founder and Vice Chairman Hans Schikan sold roughly 29,000 shares around April 29-30, collecting close to $881,000. Chief Medical Officer Peng Lu sold nearly 33,000 shares across two days for approximately $993,000. Founder and Chief Level Officer Anne Lesage also sold, disposing of around 40,900 shares for roughly $1.24 million. Together, that's close to $3 million in gross proceeds from the C-suite over a 48-hour period — all while the stock traded near $30. Over the 90-day window, net insider selling totals approximately $5.1 million. These sales follow a share price that has recovered sharply, and the cluster of simultaneous founder exits is worth noting.
Short interest tells a markedly less aggressive story. Bears pulled back hard this week. SI dropped 20% in a single week to 1.6% of free float — a level that makes it a minor factor for most traders. That retreat coincided with the stock's move higher into earnings. Cost to borrow is effectively flat at 0.48%, and borrow availability is loose, with broad supply in the lending pool relative to what is currently out on loan. There is no meaningful squeeze pressure at these levels.
Options positioning has been strikingly defensive for weeks, but the edge is fading. The put/call ratio now runs at 3.15 — in line with its 20-day average of 3.08, giving a z-score near zero. That sounds bearish in isolation, but the ratio has actually eased from its 52-week high of 4.06 hit on May 1. Options traders loaded up on downside protection ahead of the print; now that the beat is in, some of that hedging is unwinding.
The Street remains broadly constructive. Analysts from Wolfe Research initiated at Outperform with a $42 target in early April, and Wedbush nudged its target to $42 at the same time. RBC Capital holds an Outperform rating with a $51 target. Citizens trimmed its target this week — from $75 to $74 — while keeping its Market Outperform. HC Wainwright maintains a Buy at $60. The mean price target across the group is approximately $39.87, against a current price of $31.25, implying roughly 27% upside on consensus. The one outlier is the Citizens target at $74, which is well above the cluster; excluding it, the Street's center of gravity sits in the $39-51 range. Morgan Stanley and B of A targets from December 2025 ($41 and $30 respectively) remain on record but are now stale relative to the stock's recent move.
The next scheduled earnings event is August 13. The prior two reaction prints — April 2026 and November 2025 — saw the stock fall 3.7% and rise 1.2% respectively on the day, before the April event extended to a 5-day loss of 8.1%. The key clinical catalyst on the horizon is topline data from the RAPIDe-3 Phase 3 study, which represents the core bull case for deucrictibant in hereditary angioedema. Until that data lands, the stock's direction is more likely to be set by trial news flow and any formal regulatory timeline update than by the quarterly numbers.
What to watch: whether the post-earnings insider selling cluster continues into May, and whether any clinical update on RAPIDe-3 timing surfaces before the August earnings call.
See the live data behind this article on ORTEX.
Open PHVS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
